ClinPharm Consulting, a specialty pharmaceutical consulting firm with global reach, has changed its name to Kinetigen. All management, scientific and operational components of Kinetigen remain the same as under ClinPharm, including the consulting firm’s focus on clinical pharmacology and pharmacokinetics.

The change to Kinetigen is a reflection of the impact that the company has made in the pharmaceutical industry and its evolution into a leading consulting firm in clinical pharmacology and pharmacokinetics. In changing the company name, executive management determined that it was essential to develop a brand that will be easily identifiable and associated with the expertise and value that the company and its industry-leading consultants provide to clients.

“I’m thrilled to continue to build upon ClinPharm Consulting’s reputation and consultancy under our new name of Kinetigen” said Geoffrey Banks, Ph.D., president and CEO of Kinetigen. “The launch of Kinetigen is the keystone of our strategic growth initiative that will solidify our position as the go-to resource for clinical pharmacology and pharmacokinetics in the pharmaceutical industry”.

The consulting firm has grown organically over the past five years since the company was founded, and recently added senior level consultants such as David Y. Mitchell, Ph.D., former president of the American Association of Pharmaceutical Scientists (AAPS), Mark Sale, MD, former global director of modeling and simulation at GlaxoSmithKline (GSK), and Mark Bush, Ph.D., former director of pharmacokinetics at GSK.

“All of our services remain the same with the transition to Kinetigen,” said Bill Wargin, Ph.D., executive vice president and CSO, Kinetigen. “We have enhanced our SOPs and working practices, implemented more quality control procedures, and strengthened our training processes to ensure the highest quality product and services continue under Kinetigen that our clients have come to expect”.

Kinetigen’s services include:

• Pharmacokinetic analysis including non-compartmental, compartmental and population pharmacokinetic methods with industry standard software (WinNonlin, NONMEM, Monolix and NLME)
• Good Laboratory Practice (GLP) toxicokinetic analysis for determination of toxicokinetic parameters (including in-house QA capabilities and validated pharmacokinetic/ toxicokinetic analysis software)
• Interpretation of pharmacokinetic data from leading industry experts in pharmacokinetics
• Innovative model-based drug development
• Clinical trial simulations
• Authoring clinical pharmacology and pharmacokinetic sections of regulatory submissions
• Assistance with regulatory briefing documents and meetings (FDA pre-IND, EoP1, EoP2, pre-NDA, Type C meetings, etc.)
• Horizontal strategic planning across all phases of drug development
• Intelligent design of clinical studies from experts in clinical pharmacology and pharmacokinetics, including authoring clinical trial protocols and study reports
• Due diligence assessment for potential licensing of compounds